Improvement of hyperlipidemia by indomethacin in Min mice
Open Access
- 14 August 2007
- journal article
- carcinogenesis
- Published by Wiley in International Journal of Cancer
- Vol. 121 (8) , 1665-1669
Abstract
Apc gene‐deficient Min and Apc1309 mice feature a hyperlipidemic state with a markedly low expression level of lipoprotein lipase (LPL) compared to their wild‐type counterparts. We previously showed that induction of LPL mRNA by peroxisome proliferator‐activated receptor (PPAR) α and γ agonists or an LPL selective inducer suppresses both high serum lipid levels and intestinal polyp formation in these model animals. Since the general cyclooxygenase inhibitor, indomethacin, is known to suppress intestinal tumor development, but not to affect serum lipids, its influence in Min mice was here investigated. Treatment with 2.5, 5 and 10 ppm indomethacin in the diet for 14 weeks from 6 weeks of age caused significant dose‐dependent reduction in serum triglycerides, along with a reduction in the numbers of intestinal polyps to 25% of the untreated control value. LPL mRNA levels in the liver were slightly increased by indomethacin treatment. We further performed oligonucleotide microarray analysis and quantitative PCR analysis and found 8 lipid metabolism‐related genes, regulated by sterol regulatory element binding protein‐1c, to be modulated by indomethacin‐treatment in the Min mouse liver. Furthermore, TNFα was downregulated. These results indicate that indomethacin might suppress intestinal tumor formation together with a hyperlipidemic state by regulating LPL and other lipid metabolic factors.Keywords
This publication has 36 references indexed in Scilit:
- Studies with the azoxymethane–rat preclinical model for assessing colon tumor development and chemopreventionEnvironmental and Molecular Mutagenesis, 2004
- Dose‐dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligandCancer Science, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- Discordant effect of aspirin and indomethacin on intestinal tumor burden inApcMin/+ miceProstaglandins, Leukotrienes and Essential Fatty Acids, 2000
- Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situInternational Journal of Epidemiology, 1998
- Eating Patterns and Risk of Colon CancerAmerican Journal of Epidemiology, 1998
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Aspirin Use and Reduced Risk of Fatal Colon CancerNew England Journal of Medicine, 1991
- The search for the causes of breast and colon cancerNature, 1989